

Poster No	Paper Title	Presenting Author
P002	Modelling Multiple System Atrophy Disease through the generation of brain-region specific organoids	Dr Manuela Magni
P004	Dual treatment with α -synuclein oligomers and erastin increases the formation of fibrillar aggregates and decreases lipid peroxidation in HEPG2 cells.	Mr. Omer Wisam Mohammed Salih Al-ani
P006	Optimisation of a humanised mouse model for Parkinson's disease based on the combination of α -synuclein overexpression with α -synuclein fibril seeds	Miss Eline Vonck
P008	Small Extracellular Vesicles as vehicles of immunotherapeutic agents in neurodegenerative diseases.	Dr. Katerina Melachroinou
P010	Progressive and region-specific iron dysregulation in an experimental model of multiple system atrophy.	Dr Antonio Heras-Garvin
P012	Investigating Genetic Modifiers of α -Synuclein Inclusions	Dr. Bin Xiao
P014	Investigating the strain hypothesis in a gut-brain axis model of α -Synucleinopathy	Dr James Conway
P016	Modelling multi-proteinopathy in Lewy body disorders	Mr. Vasileios Theologidis
P018	Disease-specific cellular impact of alpha-synuclein aggregate strains from Parkinson's disease and multiple systems atrophy	Mr. Hjalte Gram
P020	Long-term seeding with PFFs induce oligodendroglial α -synuclein aggregation in a transgenic overexpression mouse model of MSA	Miss Anne-Line Strange Laursen
P022	Plasma-derived extracellular vesicles of patients with Parkinson's Disease Exacerbate Neuroinflammation in PFF-treated Midbrain Organoids	Mr Ankush Yadav
P024	Alterations in the nigrostriatal system following conditional inactivation of α -synuclein in neurons of adult β - or γ - knockout mice	Dr Kirill Chaprov
P026	Extracellular vesicles as mediators of neuroglial dynamics: Perspectives on MSA-related pathology	Ms. Maria Vetsi

P028	Primary enteric cultures from the colon of alpha-synuclein mice show altered Ca ²⁺ -signaling and glia distribution upon induction of alpha-synuclein pathology.	Dr Emanuela Colla
P030	Development of a novel alpha-synuclein aggregate proximity ligation assay for preclinical rodent models of synucleinopathies	Professor Poul Henning Jensen
P032	MODULATING ALPHA-SYNUCLEIN AGGREGATE PATHOLOGY IN HUMAN IPSC-DERIVED NEURONS BY SERCA INHIBITORS IN THE ABSENCE AND PRESENCE OF PRE-FORMED FIBRILS	Ms Anissa Hammi
P034	Investigating Senescence Phenotypes in Astrocytes Derived from p.A53T- α -Synuclein PD-patient iPSCs	Dr FLORENTIA PAPASTEFANAKI
P036	Examination of the effects of advanced age and features of diabetes on synucleinopathy	Dr. Joseph Patterson
P038	To validate the inflammatory phenotypes in pre-formed fibrils alpha-synuclein mice.	Dr. Jae Lee
P040	Leveraging multiple alpha-synuclein inoculation sites and machine-learning to refine neurodegeneration-based disease staging in a mouse model	Ms. Janice Park
P042	Development of α -synuclein-Specific Nanobodies for Targeting Aggregation in Parkinson's Disease	Dr. Areej Mesleh
P044	Reduction of TIA1 inhibits α -syn aggregation by elevating proteasome assembly via PSMD5 downregulation	Associate Professor Lin Yuan
P046	α -Synuclein induces deficiency in clathrin-mediated endocytosis through inhibiting synaptojanin1 expression	Postdoctor Dong-yan Song
P048	Spatiotemporal analysis of dopaminergic ALDH1A1+/- subpopulations in the midbrain of a mouse model of alpha-synuclein overexpression	Dr Niamh Connolly
P050	Alpha-synuclein monomers levels is a key determinant of pathology formation and neurodegeneration.	Dr ANNE-LAURE Mahulmellier
P052	Parkinson's Disease: From human-relevant iPSC-derived dopaminergic neuronal models to mechanisms and novel targets.	Dr ANNE-LAURE Mahulmellier

P054	An ultrastructural comparison of aSyn pathology in post-mortem human brain and iPSC-derived human dopaminergic neurons seeded with pre-formed fibrils.	Mr. Lukas van den Heuvel
P056	Development of a pocketome of alpha-synuclein fibrils as a rational tool to compare and study polymorphism	Mr. Gaëtan Ossard
P058	Myelin alterations in the skin from synucleinopathies	Ms. Marta Di Fabrizio
P060	Computational analysis of alpha-Synuclein distribution in Synucleinopathies using super-resolution microscopy	Ms Ofir Sade
P064	MicroRNA-targeted gene regulation in salivary gland tissue of de novo Parkinson's disease patients	Prof. Joong-seok Kim
P066	Studying Selective Vulnerability in Parkinson's Disease Using Spatial Transcriptomics	Dr Isar Nassiri
P068	The portal for synucleinopathy spread: Olfaction in Parkinson's disease	MD Sang-Won Yoo
P070	Suboptimal growth hormone response to clonidine in autopsy-confirmed multiple system atrophy: a potential biomarker for early diagnosis.	Dr Giacomo Chiaro
P072	Pure Autonomic Failure - a natural history study of the Queen Square cohort	Dr Giacomo Chiaro
P074	Extracellular vesicles as carriers of pathogenic α -synuclein in neurodegenerative diseases	Dr. Suman Dutta
P076	Seed amplification assay for cerebrospinal fluid from alpha-synuclein transgenic mouse models	Mrs Simone Giaisi
P078	α -Synuclein species in Synucleinopathies: peripheral features and potential biomarkers	Dr Milo Jarno Basellini
P080	A Quantitative Lewy Fold-Specific Alpha-Synuclein Aggregation Assay as a Potential Progression Marker for Parkinson's Disease	Dr Alexander Bernhardt
P082	Aggregated α -synuclein in erythrocytes as a potential biomarker for idiopathic Parkinson's Disease.	Dr Evangelia Emmanouilidou

P084	Pioneering early diagnosis of α -synucleinopathies: innovative peripheral biomarkers analysis in olfactory mucosa, urine, and blood	Dr Arianna Ciullini
P086	Role of Extracellular Vesicles in Parkinsonian disorders	Dr Cristiano Lucci
P088	Changing morphologies of α -synuclein fibrils during aggregation and storage	Dr Timothy Chisholm
P090	Stochastic misfolding drives the emergence of distinct α -synuclein strains	Dr. Joel Watts
P092	The single-cell landscape of SNCA transcript isoforms across synucleinopathies	Professor Ornit Chiba-Falek
P094	Alpha-Synuclein Strain-Based Screening Identifies Increased BCL-XL Expression in Parkinson's Disease	Mr Kreesan Reddy
P096	The LRRK2-Lewy body conundrum: Demonstration of widespread alpha-synuclein aggregate pathology in Lewy body-negative LRRK2-mutant cases	Dr Nanna Møller Jensen
P098	Delayed and Hypometric Saccades correlate with the severity of motor impairment in idiopathic Parkinson's disease.	Byungseok Kim
P100	A novel alpha-synuclein G14R missense variant is associated with atypical clinical and neuropathological features	Dr. Mohammed Al-Azzani
P102	The neuropathological signature of REM sleep behaviour disorder in selectively vulnerable brainstem nuclei and the association with Parkinson's disease	Miss Nita Alpin Dr David A Menassa
P104	Catching the structure of intermediate oligomers and protofibrils of α -synuclein	Prof. Alfonso De Simone
P106	Proximity Proteomics Reveals a Role for RNA Processing Pathways in alpha-Synuclein Aggregation	Ms. Analiese Fernandes
P108	1.94 Å structure of synthetic α -synuclein fibrils seeding MSA neuropathology	Dr François Ichas
P110	Alpha-synuclein preformed fibrils drives to synaptic abnormalities and mitochondrial dysfunction prior any neuronal death.	Dr. Noelle Callizot

P112	Molecular and mechanistic insights into alpha-synuclein's interaction with biological membrane using multi scale molecular simulations	Prof. Anand Srivastava
P114	Interplay Between α -Synuclein, Histones, and DNA interaction: Insights into α -Synuclein's Nuclear role.	Ms SNEHA JOS
P116	Exploring nuclear functions of alpha-synuclein in neurodegenerative diseases	Miss Olesya Shpironok
P118	Unveiling the protein interactome of de novo produced α -synuclein fibrils in human neurons derived from iPSCs	PhD student Chloé Baroin
P120	Interactomes of different alpha-synuclein fibrils polymorphs in neurons and astrocytes	Dr Nolwen Rey
P122	α -synuclein is a novel functional interactor of the exocyst complex	Mrs. Konstantina Dimoula
P124	First in class ASO targeting A53T allele: preclinical efficacy	Christina Tyner
P126	Development of a transferrin-receptor-binding platform to deliver antisense oligonucleotides targeting SNCA for the treatment of Parkinson's Disease	Dr. Takashi Miyamoto
P128	Astrocytic connexin 43 as an upstream target regulating inflammation and alpha-synuclein aggregation in Parkinson's	Dr Nataly Hastings
P130	SLAB51 attenuated Parkinson's disease via microbiota-gut-brain axis	Doctor Cong Feng
P132	Synaptic lipidomic changes in Parkinson's disease	Dr. Julita Chlebowicz
P134	α -Synuclein blocks endoplasmic reticulum protein translocation in Parkinson's disease	Mr ChorLai Lam
P136	Early alpha-synuclein dysfunction in a human model for Parkinson's disease	Dr Marijn Kuijpers
P138	Mutant A30P alpha-synuclein and mitochondrial dysfunction	Prof. Dr. Neville Vassallo
P140	Alterations in Mitochondrial Quality Control Proteins and Their Link to Synuclein Aggregation in Parkinson's Disease	Dr Chun Chen
P142	A Novel SGK1 Inhibitor Modulates Neurodegeneration and Neuroinflammation in an α -SYNUCLEIN Mouse Model of Parkinson's Disease	Dr. Isabel Lastres-Becker

P144	Impact of acute lipopolysaccharide-induced pneumonia on the progression of intracellular α -synuclein pathology in the PFF mouse model	Miss Alicia Katharina Rosenau
P146	Vaccines that mimic structural epitopes on α -synuclein fibrils offer protection against Parkinson's disease	Prof. Dr. Gültekin Tamgüney
P148	The influence of vagus-mediated immune modulation in the progression of Parkinson's disease	Ms. Ida Klastrup
P150	Chronic urinary tract infections cause persistent microglial changes in a humanized α -synuclein mouse model	Miss Ann-Céline Clabout
P152	Evaluation of IGFBPL1 as a potential biomarker for PD progression	Dr EMMANOUELA LEANDROU
P154	Alpha-synuclein fine-tunes neuronal response to pro-inflammatory cytokines	Ms. Veronika Sigutova
P156	Vascular pathology induced by alpha-synuclein overexpression renders the brain more vulnerable to bacterial endotoxins	Mrs. Kristina Lau
P158	Targeting alpha-synuclein aggregation using helix-constrained peptide inhibitors	Mr Scott Allen
P160	Identifying mechanisms regulating α -synuclein degradation by CRISPR knockout screening	Dr Andrew Castle
P162	Dissecting the role of the autophagy-lysosome pathway in human MSA	Ms. Fedra Arvanitaki
P164	Poly- γ -glutamic acid affects the clearance of pre-formed fibrils of α -Synuclein and modulates inflammation in murine primary astrocytes	Dr Claudia Novello
P166	The inhibition of α -synuclein aggregation using marine-derived bacterial metabolites as a novel neuroprotective approach for Parkinson's Disease	Ms Christina Machalia
P168	Axonal transport of alpha-synuclein prion strains	Mr Chase Khedmatgozar
P170	TARGETING THE SERCA TRANSPORTER TO RESTORE NEURONAL Ca^{2+} BALANCE: A NEW APPROACH FOR PARKINSON'S DISEASE TREATMENT	Mr Lasse Reimer
P172	Investigating the functional role of alpha-synuclein in exosome biogenesis and secretion in Parkinson's pathogenesis.	Ms. Sharanya Thevasenan

P174	A genome-wide microRNA screen uncovers modifiers of alpha-synuclein fibril internalization	Lea Nikolić
LB01	Pathological aggregates induce gel-like proteasome condensates that facilitate degradation of protein aggregates	Dr Yu Ye